Добірка наукової літератури з теми "EXtremely Drug Resistant Tuberculosis"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "EXtremely Drug Resistant Tuberculosis".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "EXtremely Drug Resistant Tuberculosis"
Polsfuss, Silke, Sabine Hofmann-Thiel, Matthias Merker, David Krieger, Stefan Niemann, Holger Rüssmann, Nicolas Schönfeld, Harald Hoffmann, and Katharina Kranzer. "Emergence of Low-level Delamanid and Bedaquiline Resistance During Extremely Drug-resistant Tuberculosis Treatment." Clinical Infectious Diseases 69, no. 7 (February 2, 2019): 1229–31. http://dx.doi.org/10.1093/cid/ciz074.
Повний текст джерелаMigliori, G. B., R. Centis, L. D'Ambrosio, A. Spanevello, E. Borroni, D. M. Cirillo, and G. Sotgiu. "Totally Drug-Resistant and Extremely Drug-Resistant Tuberculosis: The Same Disease?" Clinical Infectious Diseases 54, no. 9 (April 9, 2012): 1379–80. http://dx.doi.org/10.1093/cid/cis128.
Повний текст джерелаAntonenko, Kate, Valentin Kresyun, and Peter Antonenko. "Mutations leading to drug-resistant Mycobacterium tuberculosis infection in Ukraine." Open Medicine 5, no. 1 (February 1, 2010): 30–35. http://dx.doi.org/10.2478/s11536-009-0114-6.
Повний текст джерелаAllué-Guardia, Anna, Rajagopalan Saranathan, John Chan, and Jordi B. Torrelles. "Mycobacteriophages as Potential Therapeutic Agents against Drug-Resistant Tuberculosis." International Journal of Molecular Sciences 22, no. 2 (January 13, 2021): 735. http://dx.doi.org/10.3390/ijms22020735.
Повний текст джерелаMumena, David Kajoba, Geoffrey Kwenda, Caroline Wangari Ngugi, and Andrew Kimanga Nyerere. "Drug-Resistant Tuberculosis Types and Their Treatment Regimens Using First-Line, Second-Line Injectable, Third-Line, Fluoroquinolones, Aminoglycosides, Cyclic Polypeptides, Novel and Repurposed Anti-Tuberculosis Drugs." Journal of Biomedical Research & Environmental Sciences 3, no. 8 (September 2022): 988–93. http://dx.doi.org/10.37871/jbres1542.
Повний текст джерелаShen, Xin, Guo-miao Shen, Jie Wu, Xiao-hong Gui, Xia Li, Jian Mei, Kathryn DeRiemer, and Qian Gao. "Association between embB Codon 306 Mutations and Drug Resistance in Mycobacterium tuberculosis." Antimicrobial Agents and Chemotherapy 51, no. 7 (April 16, 2007): 2618–20. http://dx.doi.org/10.1128/aac.01516-06.
Повний текст джерелаPecho-Silva, Samuel, Ana Claudia Navarro-Solsol, Vicky Panduro-Correa, Jorge L. Maguina, Ali A. Rabaan, Luis Rene Quiroz-Ramirez, Kovy Arteaga-Livias, and Alfonso J. Rodriguez-Morales. "The first successful cochlear implant in Latin America after severe aminoglycoside-induced ototoxicity in a Peruvian patient cured of extensively drug-resistant tuberculosis." Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo 15, no. 4 (February 8, 2023): 622–25. http://dx.doi.org/10.35434/rcmhnaaa.2022.154.1501.
Повний текст джерелаYadav, Snehlata, and Balasubramanian Narasimhan. "New Insights in Design and Development of Antitubercular Drugs." Current Bioactive Compounds 16, no. 1 (February 20, 2020): 13–23. http://dx.doi.org/10.2174/1573407215666190409153756.
Повний текст джерелаShaji, Jessy, and Mahmood Shaikh. "DRUG-RESISTANT TUBERCULOSIS: RECENT APPROACH IN POLYMER BASED NANOMEDICINE." International Journal of Pharmacy and Pharmaceutical Sciences 8, no. 10 (August 12, 2016): 1. http://dx.doi.org/10.22159/ijpps.2016v8i10.11295.
Повний текст джерелаVelayati, A. A., P. Farnia, M. A. Merza, G. K. Zhavnerko, P. Tabarsi, L. P. Titov, J. Ghanavei, et al. "New insight into extremely drug-resistant tuberculosis: using atomic force microscopy." European Respiratory Journal 36, no. 6 (November 30, 2010): 1490–93. http://dx.doi.org/10.1183/09031936.00064510.
Повний текст джерелаДисертації з теми "EXtremely Drug Resistant Tuberculosis"
Smith, Louise. "Resilience of the partners of long term hospitalised patients with multidrug-resistant (MDR) and extreme drug-resistant (XDR) tuberculosis (TB)." Thesis, Nelson Mandela Metropolitan University, 2013. http://hdl.handle.net/10948/d1020913.
Повний текст джерелаSeddon, James Alexander. "Drug-resistant tuberculosis in children." Thesis, London School of Hygiene and Tropical Medicine (University of London), 2012. http://researchonline.lshtm.ac.uk/4646555/.
Повний текст джерелаPatel, Fadheela. "Development of a cost-effective drug sensitivity test for multi-drug resistant and extensively drug-resistant tuberculosis." Thesis, Cape Peninsula University of Technology, 2010. http://hdl.handle.net/20.500.11838/1496.
Повний текст джерелаThe World Health Organisation estimates that nine million people are infected with tuberculosis (TB) every year of which ninety-five percent live in developing countries. Africa has one of the highest incidences of TB in the world. but few of its countries are equipped to diagnose drug-resistant TB. This study aimed to develop a robust. yet simple and cost-effective assay. which would require minimal sophisticated instrumentation and specialised personnel that would make drug sensitivity screening for multi-drug resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) accessible to resource-poor high-burden settings. A four-quadrant colorimetric agar plate method was developed which showed good specificity (97.3%-100%) and sensitivity (77.8%-100%) compared to the polymerase chain reaction (PCR) method used as gold standard. Agreement between the methods. using Simple Kappa Coefficients. ranged between very good and excellent. all with high statistical significance (P < 0.0001). The currently used BACTEC MGIT SIREN sensitivity assay coupled with the E-test® strip method. as routinely used in the TB reference laboratory. was compared and showed excellent comparison with the newlydeveloped plate method. for each antibiotic tested. as well as the resultant monoresistant, MDR- or XDR-TB diagnoses. Moreover. the new method was found to be extremely cost-effective. priced at half the cost of a peR assay. These four quadrant plates. with a colorimetric indicator and selected antibiotics. can be considered as an economic altemative or a complimentary method for laboratories wishing to reduce the cost and complexity for TB drug sensitivity testing. Routine diagnostic testing would thus be made more accessible and affordable to laboratories that are not presently diagnosing drug resistant TB. therefore enhancing case detection and treatment in the resource-poor settings hardest hit by this curable disease.
Krüüner, Annika. "Drug-resistant Mycobacterium tuberculosis in Estonia /." Stockholm, 2003. http://diss.kib.ki.se/2003/91-7349-455-0/.
Повний текст джерелаDubiniecki, Christine. "Drug resistant tuberculosis in Montreal 1992-1995." Thesis, McGill University, 2001. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=33751.
Повний текст джерелаStudy design. Retrospective descriptive analysis Study population. All culture proven TB patients reported to the Montreal Regional Health Board aged 0--49 for 1992--1994 and 0--18 years for 1995.
Results. Drug resistant TB was found in 18.3% of culture-proven TB cases. The rate of INH resistance in our study cohort was 10.6%. Two percent of TB cases were found to have MDR-TB. Only 3 TB cases (0.9%) in our study cohort developed acquired drug resistance over the study period. Previous history of TB was associated with a 3.9 times greater risk of drug resistant TB.
Conclusions. Drug resistance is a significant problem in Montreal that continues to hinder TB treatment and control. Previous history of tuberculosis is a strong predictor of drug resistance. In addition, immigration from individual countries was not associated with an increase in the rate of drug resistance. Nonetheless, country-specific drug resistance rates may serve to predict the likelihood of drug resistant TB among the foreign-born in Canada.
Ford, Christopher Burton. "The Evolution of Drug Resistant Mycobacterium Tuberculosis." Thesis, Harvard University, 2012. http://dissertations.umi.com/gsas.harvard:10596.
Повний текст джерелаShean, Karen Penelope. "Extensively drug resistant tuberculosis in South Africa." Master's thesis, University of Cape Town, 2011. http://hdl.handle.net/11427/11620.
Повний текст джерелаIncludes bibliographical references (leaves 161-168).
There are few data for treatment-related outcomes in patients with XDR tuberculosis in settings with high HIV prevalence. We reviewed the case records of 227 consecutively diagnosed South African patients with XDR-TB between 2002 and 2008, and analysed the records of another 115 patients, retrospectively, for adverse drug reactions (ADRs). It was found that a significant proportion of XDR-TB patients are HIV unrelated, and prognosis, regardless of HIV status, poor. Nevertheless, survival in HIV infected patients is better than previously reported, and treatment with HAART improves outcomes. The frequency of ADR’s with XDR-TB treatment regimens is high, often severe, and negatively impacts on culture conversion outcomes. These data have implications for the formulation of recommendations for control programmes in resource-poor settings.
Al-Shammaa, Zaid. "Targeting Drug-Resistant Tuberculosis Using SMART Nanotechnology Approach." University of Cincinnati / OhioLINK, 2015. http://rave.ohiolink.edu/etdc/view?acc_num=ucin1439310613.
Повний текст джерелаStoffels, Karolien. "Contribution to the research on drug resistant Mycobacterium tuberculosis." Doctoral thesis, Universite Libre de Bruxelles, 2014. http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/209194.
Повний текст джерелаFirst of all, a profound analysis of the MDR-TB situation in Belgium was conducted. It is the first retrospective population-based survey of MDR-TB in Belgium, covering a 15-year period (1994-2008). It comprises 174 patients representing more than 80% of the culture positive MDR-TB patients reported to the Belgian register, thus this study is considered of national relevance. It includes bacteriological and molecular data on the isolates as well as clinical aspects of the patients and treatment results. Considering only the patient’s first MDR-TB isolate, an increase over time was observed in the number of isolates resistant to a second-line drug as well as the total number of drugs each isolate was resistant to. XDR-TB was detected since 2002 and panresistant TB (resistant to every available antituberculosis drug) since 2009. Overall, a successful treatment outcome was obtained for 67.8% of the MDR-TB cases. Drug susceptibility testing (DST) of Mycobacterium tuberculosis to first line drugs (isoniazid, rifampicin, ethambutol and pyrazinamide) in liquid culture medium has a turn around time of at least two weeks, after identification of the positive culture (obtained after 2 to 4 weeks) from the patient’s clinical isolate. In order to provide the clinician with valuable information about the isolated mycobacteria leading to patient adapted therapy before bacteriological DST results are available, resistance is predicted by detection of mutations in certain genes of the mycobacteria. It is common practice for rifampicin (rpoB gene) and isoniazid (katG gene and/or inhA promoter region). In this MDR-TB collection, rifampicin resistant related mutations were found in 97.1% (168/173) of the clinical isolates and isoniazid resistant related mutations in 94.1% (160/170). The pncA, embB and gyrA genes have been sequenced to identify possible mutations because of their possible involvement with resistance to pyrazinamide, ethambutol and the fluoroquinolones respectively. However, little is known about the resistance prediction value of the mutations in these genes.
The study is also the first study on the molecular epidemiology of MDR-TB in the country. DNA fingerprinting showed a large diversity of strains (67% of the patients were infected by a strain with a unique pattern) and further epidemiological examination revealed limited local transmission of MDR-TB in Belgium.
The second part investigated the pncA gene and its association with pyrazinamide resistance in MDR-TB isolates from Belgium and in vitro cultured spontaneous mutants. The genetic analysis showed that 98.3% (59/60) of the Belgian clinical MDR pyrazinamide resistant (PZAR) isolates present a mutation in the pncA gene. We found 1.7% (1/60) of the PZAR MDR-isolates encoding wild type pncA and flank. A total (PZAR and PZAS) of 41 different amino acid changes, 3 protein truncations and 5 frameshifts were observed including eight novel mutations: 8Asp>Ala, 13Phe>Leu, 64Tyr>Ser, 107Glu>stop, 143Ala>Pro, 172Leu>Arg and frameshifts starting in codon 55 and 82. Analysis of all observed mutations (i.e. in clinical isolates as well as spontaneous mutants) revealed that they are not always associated with drug resistance and that they are not scattered randomly throughout the gene, but occur rather at preferential sites such as in codons with amino acids associated with either iron or substrate binding and catalytic active sites. The frequency of in vitro mutagenesis to pyrazinamide at pH 6.0 was determined and found to be relatively high at 10-5 CFU/ml.
Finally, the in vitro activity of tobramycin and clarithromycin (with unclear efficacy against M. tuberculosis) was evaluated on 25 M. tuberculosis clinical isolates with various resistance profiles. The effect of the drugs administered together was examined for possible synergistic effect. The median minimum inhibitory concentration (MIC) of 8 µg/ml obtained for both drugs in this study is rather high but are beyond the concentrations obtained in lung tissues. This suggests that both drugs should be investigated further as potential adjuncts to the treatment of resistant TB when other alternatives have failed; in particularly through new drug delivery systems such as the Dry Power Inhaler which allows local drug deposition with high drug concentrations in the lungs but low toxicity due to limited systemic absorption. In addition, for 36% of the tested isolates a decrease of the MIC of clarithromycin by a single or twofold dilution was observed in the presence of a subinhibitory concentration of tobramycin and no antagonistic effect was seen for the remaining isolates.
This research illustrates different (laboratory) aspects in the fight against drug resistant TB, all using the Belgian TB collection: characterisation of the Belgian MDR-TB situation on bacteriological, molecular and epidemiological level; profound analysis of genomic mutations and their possible association with drug resistance; and investigation of synergistic activity of drugs with low efficacy against M. tuberculosis.
Doctorat en Sciences biomédicales et pharmaceutiques
info:eu-repo/semantics/nonPublished
Kwong, Tsz-ching, and 鄺芷晴. "The role of molecular diagnosis of drug resistant tuberculosis." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2015. http://hdl.handle.net/10722/208588.
Повний текст джерелаpublished_or_final_version
Microbiology
Master
Master of Philosophy
Книги з теми "EXtremely Drug Resistant Tuberculosis"
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (U.S.). Division of Tuberculosis Elimination. TB elimination: Treatment of drug-resistant tuberculosis. Atlanta, Ga.]: National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Division of Tuberculosis Elimination, 2012.
Знайти повний текст джерелаHarvard Medical School. Program in Infectious Disease and Social Change. and Open Society Institute, eds. The global impact of drug-resistant tuberculosis. Boston, MA: Program in Infectious Disease and Social Change, Dept. of Social Medicine, Harvard Medical School, 1999.
Знайти повний текст джерелаNguy, Shui. Drug-resistant tuberculosis: Causes, diagnosis, and treatments. Edited by K'ung Zhou. Hauppauge NY: Nova Science Publishers, 2009.
Знайти повний текст джерелаCrofton, John. Guidelines for the management of drug-resistant tuberculosis. Geneva: World Health Organization, 1997.
Знайти повний текст джерелаCrofton, John Wenman. Guidelines for the management of drug-resistant tuberculosis. Geneva: World Health Organization, 1997.
Знайти повний текст джерелаJohn, Crofton. Guidelines for the management of drug-resistant tuberculosis. Geneva: WHO, 1997.
Знайти повний текст джерелаJohn, Crofton. Guidelines for the management of drug-resistant tuberculosis. Geneva: World Health Organization, 1997.
Знайти повний текст джерелаGuidelines on the management of drug-resistant tuberculosis. [Geneva]: World Health Organization, 1997.
Знайти повний текст джерелаN, Rom William, and Garay Stuart M, eds. Tuberculosis. Boston: Little, Brown, 1996.
Знайти повний текст джерелаMichael, Rich, and World Health Organization, eds. Guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: World Health Organization, 2006.
Знайти повний текст джерелаЧастини книг з теми "EXtremely Drug Resistant Tuberculosis"
Dheda, Keertan, Aliasgar Esmail, Anzaan Dippenaar, Robin Warren, Jennifer Furin, and Christoph Lange. "Drug-Resistant Tuberculosis." In Clinical Tuberculosis, 301–26. Sixth edition. | Boca Raton, FL : CRC Press/Taylor & Francis Group, 2020.: CRC Press, 2020. http://dx.doi.org/10.1201/9781351249980-16.
Повний текст джерелаDavies, Peter D. O. "Multi-Drug-Resistant Tuberculosis." In Tuberculosis, 809–37. Berlin, Heidelberg: Springer Berlin Heidelberg, 2004. http://dx.doi.org/10.1007/978-3-642-18937-1_46.
Повний текст джерелаLiang, Lili, Yun Ma, Xin liu, and Yamin Lv. "Drug-Resistant Tuberculosis." In Drug Resistance in Bacteria, Fungi, Malaria, and Cancer, 193–208. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-48683-3_8.
Повний текст джерелаAhmad Khan, Faiz, Greg Fox, and Dick Menzies. "Drug-Resistant Tuberculosis." In Handbook of Antimicrobial Resistance, 1–20. New York, NY: Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4939-0667-3_13-1.
Повний текст джерелаAhmad Khan, Faiz, Greg Fox, and Dick Menzies. "Drug-Resistant Tuberculosis." In Handbook of Antimicrobial Resistance, 263–86. New York, NY: Springer New York, 2017. http://dx.doi.org/10.1007/978-1-4939-0694-9_13.
Повний текст джерелаBachappanavar, Nikhil, and Sinosh Skariyachan. "Combinatorial Designing of Novel Lead Molecules Towards the Putative Drug Targets of Extreme Drug-Resistant Mycobacterium tuberculosis: A Future Insight for Molecular Medicine." In Essentials of Bioinformatics, Volume II, 233–81. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-18375-2_12.
Повний текст джерелаJohnson, Livette S., and Kent A. Sepkowitz. "Treatment of multi-drug-resistant tuberculosis." In Tuberculosis, 317–30. Boston, MA: Springer US, 1995. http://dx.doi.org/10.1007/978-1-4899-2869-6_13.
Повний текст джерелаXiao, Heping, Shenjie Tang, Wei Sha, Qing Zhang, and Jin Zhao. "Drug-Resistant TB." In Handbook of Global Tuberculosis Control, 135–56. Boston, MA: Springer US, 2017. http://dx.doi.org/10.1007/978-1-4939-6667-7_10.
Повний текст джерелаSchluger, Neil W. "Extensively Drug-Resistant Tuberculosis." In Emerging Infections 8, 337–53. Washington, DC, USA: ASM Press, 2014. http://dx.doi.org/10.1128/9781555815592.ch17.
Повний текст джерелаAuld, Sara C., Neel R. Gandhi, and James C. M. Brust. "Drug-Resistant Tuberculosis and HIV." In HIV and Tuberculosis, 203–37. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-29108-2_10.
Повний текст джерелаТези доповідей конференцій з теми "EXtremely Drug Resistant Tuberculosis"
ankale, Padmaraj, Girija Nair, Abhay Uppe, Aleena Mathew, and Ria shah. "Socioeconomic Conditions Contributing to Multi Drug Resistant (MDR) and Extremely Drug Resistant(XDR) Tuberculosis." In ERS International Congress 2017 abstracts. European Respiratory Society, 2017. http://dx.doi.org/10.1183/1393003.congress-2017.pa2727.
Повний текст джерелаSung, Nacmoon, Jeong Su Cho, Ki-Hong Kim, Jong-Ki Kim, JinHee Jung, Hyungseok Kang, Seungkyu Park, and Sanghoon Jheon. "Inactivation Of Multidrug Resistant (MDR)- And Extremely Drug Resistant (XDR)-Mycobacterium Tuberculosis Strains By Using Photodynamic Therapy (PDT)." In American Thoracic Society 2010 International Conference, May 14-19, 2010 • New Orleans. American Thoracic Society, 2010. http://dx.doi.org/10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a3170.
Повний текст джерелаWaghmare, Manoj, Ketaki Utpat, Unnati Desai, and Jyotsna Joshi. "Drug resistant tuberculosis at a drug resistant tuberculosis centre, India- Analysis of outcome." In ERS International Congress 2017 abstracts. European Respiratory Society, 2017. http://dx.doi.org/10.1183/1393003.congress-2017.pa2729.
Повний текст джерелаArtiom, Jucov, and Lesnic Evelina. "Social determinants of drug-susceptible and drug resistant tuberculosis." In ERS International Congress 2016 abstracts. European Respiratory Society, 2016. http://dx.doi.org/10.1183/13993003.congress-2016.pa2749.
Повний текст джерелаCarroll, Matthew W., M. S. Lee, T. S. Song, Ying Cai, J. S. Lee, Y. M. Lee, L. E. Via, et al. "Linezolid For Extensively Drug Resistant Pulmonary Tuberculosis." In American Thoracic Society 2011 International Conference, May 13-18, 2011 • Denver Colorado. American Thoracic Society, 2011. http://dx.doi.org/10.1164/ajrccm-conference.2011.183.1_meetingabstracts.a1838.
Повний текст джерелаHidayathillah, Ariska Putri, Chatarina Umbul W, and Hari Basuki N. "Index Predictive of Drug Resistant Tuberculosis (MDR-TB) on Tuberculosis Patients." In The 2nd International Symposium of Public Health. SCITEPRESS - Science and Technology Publications, 2017. http://dx.doi.org/10.5220/0007511902270231.
Повний текст джерелаCampos, Michael Ramírez, Diana C. Rodríguez, and Alvaro D. Orjuela-Cañón. "Molecular Compounds Proposal for Drug-Resistant Tuberculosis in the Drug Discovery Process." In 2023 IEEE Colombian Conference on Applications of Computational Intelligence (ColCACI). IEEE, 2023. http://dx.doi.org/10.1109/colcaci59285.2023.10225875.
Повний текст джерелаChopra, Manu, C. D. S. Katoch, G. D. S. Madan, and Barun Chakrabarty. "Outcomes of directly observed treatment for drug resistant tuberculosis." In ERS International Congress 2016 abstracts. European Respiratory Society, 2016. http://dx.doi.org/10.1183/13993003.congress-2016.pa2687.
Повний текст джерелаMoodliar, R., V. Aksenova, M. V. G. Frias IV, J. van de Logt, S. Rossenu, E. Birmingham, C. Kambili, et al. "Bedaquiline for Multi Drug-Resistant, Including Extensively or Pre-Extensively Drug-Resistant, Pulmonary Mycobacterium Tuberculosis in Children." In American Thoracic Society 2020 International Conference, May 15-20, 2020 - Philadelphia, PA. American Thoracic Society, 2020. http://dx.doi.org/10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a1050.
Повний текст джерелаMadhav, Bhumika, Aparna Iyer, and T. K. Jayalakshmi. "Side effect profile of 2ndline drugs in multi drug resistant (MDR) and extensively drug resistant (XDR) tuberculosis." In Annual Congress 2015. European Respiratory Society, 2015. http://dx.doi.org/10.1183/13993003.congress-2015.pa2708.
Повний текст джерелаЗвіти організацій з теми "EXtremely Drug Resistant Tuberculosis"
Yusim, Karina, Bette T. M. Korber, Shihai Feng, and Chang-Shung Tung. Compensatory mutation in RpoC restores fitness to rifampicin-resistant multi-drug resistant Mycobacterium tuberculosis. Office of Scientific and Technical Information (OSTI), August 2012. http://dx.doi.org/10.2172/1049993.
Повний текст джерелаLau, J., and B. Baker. Isothermal DNA Assay to Detect Drug-Resistant Tuberculosis for Point-of-Care Diagnostics. Office of Scientific and Technical Information (OSTI), August 2013. http://dx.doi.org/10.2172/1093910.
Повний текст джерелаRapid tests for diagnosing drug resistant tuberculosis are accurate and may be cost effective. National Institute for Health Research, November 2015. http://dx.doi.org/10.3310/signal-000145.
Повний текст джерела